A case of pancreatic cancer after heart transplantation

Int Heart J. 2012;53(3):205-7. doi: 10.1536/ihj.53.205.

Abstract

Malignancy is not uncommon with immunosuppressive therapy, but pancreatic cancer is infrequently complicated in recipients of heart transplantation. Here we report a transplant case diagnosed with pancreatic cancer 4 years and 8 months after the heart transplantation. We changed the immunosuppressive regimen after the malignancy was detected, and administered everolimus along with chemotherapy using S-1, an oral fluoropyrimidine prodrug. The patient lived for 8 months after the diagnosis, and received metallic stenting for the biliary and duodenal obstruction. Also, to the best of our knowledge, this is the first report about chemotherapy and endoscopic intervention for pancreatic cancer in a heart transplantation patient.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / chemically induced
  • Adenocarcinoma / diagnosis*
  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy
  • Antimetabolites, Antineoplastic / adverse effects
  • Antimetabolites, Antineoplastic / therapeutic use
  • Cholestasis, Extrahepatic / diagnosis
  • Cholestasis, Extrahepatic / therapy
  • Combined Modality Therapy
  • Drug Combinations
  • Drug Therapy, Combination
  • Duodenal Obstruction / diagnosis
  • Duodenal Obstruction / therapy
  • Everolimus
  • Follow-Up Studies
  • Graft Rejection / drug therapy
  • Heart Transplantation*
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Myocardial Ischemia / surgery*
  • Neoplasm Staging
  • Oxonic Acid / therapeutic use
  • Pancreatic Neoplasms / chemically induced
  • Pancreatic Neoplasms / diagnosis*
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / therapy
  • Postoperative Complications / diagnosis*
  • Postoperative Complications / therapy
  • Sirolimus / adverse effects
  • Sirolimus / analogs & derivatives
  • Sirolimus / therapeutic use
  • Stents
  • Tegafur / therapeutic use

Substances

  • Antimetabolites, Antineoplastic
  • Drug Combinations
  • Immunosuppressive Agents
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
  • Everolimus
  • Sirolimus